-
May 21, 2012, 00:05 AM
by
Michael Croft
Zacks | Accelrys has bought a Cloud-based drug discovery and development platform from SCYNEXIS, completing the contract both companies entered into last year.
Full story
-
May 21, 2012, 00:05 AM
by
Michael Croft
Bloomberg | In a paper released last week in Science, researchers at the University of Washington show that most genetic variations in people are rare and evolutionarily recent. The findings further reinforce the changes being made to how we think about correlating genetic changes with diseases.
Full story
-
May 18, 2012, 01:00 AM
by
Michael Croft
New York Times | Human Genome Sciences is still rejecting a bid from GlaxoSmithKline to buy the biotech. Human Genome Sciences' board voted unanimously to reject the GSK offer and adopt a shareholders' rights plan, or poison pill.
Full story
-
May 17, 2012, 03:00 AM
by
Michael Croft
2012 Bio-IT World Best Practices Winner | “It’s survival of the fittest,” explains Ulrich Betz, department head of Merck Serono’s Innovation & Entrepreneurship Incubator, of Merck’s innospire program, winner of the 2012 Bio-IT World Best Practices award for Knowledge Management. Only the best ideas win.
Full story
-
May 17, 2012, 02:00 AM
by
Michael Croft
Wall Street Journal | Pfizer's new lung cancer drug is showing effectiveness against childhood cancers with defects in the ALK gene.
Full story
-
May 16, 2012, 03:00 AM
by
Michael Croft
Bio-IT World | BGI has garnered a lot of attention for its sheer sequencing capacity. Now the sequencing center has installed a new Roche GS FLX+ System at its Shenzhen facility to enhance BGI's long read sequencing capabilities and supplement the short read technologies.
Full story
-
May 16, 2012, 02:05 AM
by
Michael Croft
Fox Business | GlaxoSmithKline has purchased the remaining percentage of Cellzome for about $98 million in cash.
Full story
-
May 16, 2012, 02:00 AM
by
Michael Croft
Forbes | Last year NIH set up the National Center for Advancing Translational Sciences to overcome bottlenecks and accelerate the development of diagnostics and therapeutics. Recently, the Center's mandate has been further expanded.
Full story
-
May 15, 2012, 04:00 AM
by
Michael Croft
Bio-IT World | 454 Life Sciences and SoftGenetics have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe software.
Full story
-
May 14, 2012, 01:00 AM
by
Michael Croft
Bio-IT World | Limitations on the use of observational data in comparative effectiveness research (CER) were among the themes of a Post-Approval Summit held in early May at Harvard Medical School*. The march toward bigger and often mandatory post-approval studies needs to be rooted in “strong science,” enabled by industry partnerships with large health care delivery organizations, insurers, the Food and Drug Administration (FDA), and academia, according to keynote speaker Michael Rosenblatt, executive vice president and chief medical officer at Merck.
Full story
-
May 11, 2012, 01:15 AM
by
Michael Croft
2012 Bio-IT World Best Practices Winner | Almost a year ago, Pfizer started recruiting for a different kind of clinical trial: the first ever conducted under a Participatory Patient-Centered (PPC) model. Last month, the team’s efforts—still very much ongoing—were rewarded with a Bio-IT World Best Practices Award in the Clinical and Health IT category.
Full story
-
May 11, 2012, 01:00 AM
by
Michael Croft
MIT News | Researchers at MIT and Dana Farber have shown that staggering cancer drugs produces better results--in very specific ways. The results were published in Cell today.
Full story
-
May 10, 2012, 02:05 AM
by
Michael Croft
Xconomy | We are generally agreed that the analysis side of the next generation sequencing coin is becoming the toughest. Even if you get your sequence in a day, then you have to process it.
Full story
-
May 10, 2012, 02:00 AM
by
Michael Croft
Baltimore Sun | GlaxoSmithKline has launched a hostile takeover bid for long-time partner Human Genome Sciences worth $2.6 billion, or $13/share.
Full story
-
May 9, 2012, 04:00 AM
by
Michael Croft
Bio-IT World | BOSTON—Manolis Kellis, professor of computer science at MIT, addressed the Bio-IT World Conference on efforts to revolutionize the study of human disease by bridging the gap between genetics and epigenetics.
Full story
-
May 8, 2012, 03:30 AM
by
Michael Croft
Technology Review | Bina Technologies is throwing its hat into the genome analysis ring with an in-house analyzer that can upload the resulting genetic profiles to the company's cloud-hosted site for data management, sharing, and aggregation.
Full story
-
May 8, 2012, 00:05 AM
by
Michael Croft
Bio-IT World | Bio-IT World has invited a group of superb world-renowned speakers from across Asia, Europe, and North America for its very first conference in Asia (Marina Bay Sands, Singapore; June 6-8, 2012). They will present the latest advances in research and technology in areas such as next-gen sequencing, personalized medicine, high-performance and cloud computing, bioinformatics, drug discovery and development, and translational research. Read on for some of the editor's favorites.
Full story
-
May 7, 2012, 03:05 AM
by
Michael Croft
Bio-IT World | BOSTON—Alex Sherman, director of systems in neurology at Massachusetts General Hospital (MGH) presented promising new initiatives in the battle against rare diseases at the Bio-IT World Conference. Sherman proposed a model for dealing with the many obstacles that confront research on rare diseases.
Full story
-
May 7, 2012, 03:00 AM
by
Michael Croft
Forbes | Thanks to enabling legislation and differing clinical trials requirements, Europe moves further ahead in biosimilar sales.
Full story
-
May 4, 2012, 03:00 AM
by
Michael Croft
Bio-IT World | BOSTON—“Filter my words accordingly; I’m not a pundit or visionary,” began Chris Dagdigian in a superfluous introduction to his annual “trends in the trenches” review at the Bio-IT World Expo last week.
Full story
